

show only low activity. To fully understand the underlying structural principles behind functional activity shifts we have crystallized and solved the structures of all four hybrid proteins. Our results show that the overall polypeptide chain fold for these four hybrid proteins is similar to that of IL-8. However, also apparent are differential side chain interactions that appear to be correlated to observed functional differences. This has led to a hypothesis as to which portions of the surface of IL-8 are essential for the expression of its activity.

**PS04.15.15 STRUCTURAL STUDIES OF CATALYTIC ANTIBODIES.** A. Heine, E. A. Stura, K. D. Janda, C. F. Barbas III, R. A. Lerner, I. A. Wilson, The Scripps Research Institute, Department of Molecular Biology, 10666 North Torrey Pines Road, La Jolla, CA 92037.

The diversity of the immune system can be exploited to generate catalytic antibodies, which not only catalyze a wide variety of reactions similar to enzymes, but also otherwise disfavored or difficult reactions. The structures of catalytic antibodies and their corresponding complexes with transition state analogs or substrates are essential to understand the antibody-antigen interaction and the mechanism involved in catalysis. A comparison of such mechanisms with those of corresponding enzymes might give indications for different rate enhancements. By knowing which residues in the active site are involved in catalysis, site directed mutagenesis can be done to improve the catalytic rate.

The aldolase antibody 38C2 mimics the natural class I aldolase enzyme. A similar mechanism for catalysis is proposed. The  $\epsilon$ -amino group of a lysine residue in the active site forms an enamine with a ketone substrate, activating it as an aldol donor. Crystals diffract to at least 3.2 Å and a dataset was collected to that resolution. Subsequently studied antibodies include the anti-metalloocene antibody 13G5, which catalyzes a Diels-Alder reaction. A ferrocene derivative was used as the haptenic group. Data were collected to 2.7 Å for the Fab and to 2.8 Å for the isomorphous complex. A syn elimination of an acyclic substrate is catalyzed by antibody 1D4. In the absence of the catalytic antibody this disfavored reaction does not occur. Crystallization conditions, structure solution and progress in refinement will be reported.

**PS04.15.16 STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN  $\kappa_{IV}$  LIGHT CHAIN LEN.** D.-B. Huang, C. Ainsworth, C.-H. Chang, F. J. Stevens, M. Schiffer, Center for Mechanistic Biology and Biotechnology, Argonne National Laboratory, Argonne, IL 60439-4833

The structure of  $\kappa_{IV}$  protein LEN was determined using molecular replacement with the  $\kappa_I$  protein REI as a search structure. The R factor is 15% for data extending to 1.8 Å. The protein was crystallized from 1.5 M ammonium sulfate in space group C222<sub>1</sub>; the unit cell dimensions are  $a=43.1$ ,  $b=83.5$ , and  $c=54.5$  Å. There is one V domain in the asymmetric unit. The crystallographic twofold axis parallel to the b axis forms the twofold of the dimer observed in other crystal structures of light chains. Although the geometry of this dimer is similar to that observed in human  $\kappa_I$  type protein REI and mouse protein McPC603, the crystal contacts are different. The LEN dimers form a very tightly packed crystal, with head to tail contacts. All other kappa V domain dimers form a helix related by the sixfold screw axis of the unit cell; the contacts between neighboring dimers are through residues 9-12 forming a  $\beta$ -pleated sheet utilizing a local or crystallographic twofold axis. We speculate that this contact in the LEN crystal is not energetically favorable, since Ser residues 9 and 12 are replaced by Asp and Ala, respectively. Protein LEN has six additional residues in its CDR1 segment compared with REI. The LEN CDR1 segment

has the same length as murine  $\kappa$  light chain McPC603; its amino acid sequence differs in 5 out of 17 residues. The conformations of these segments are also homologous. Proteins with closely related sequences to LEN form various deposits in patients, while LEN does not; therefore it can serve as a standard to identify pathogenic features of light chains.

This work was supported by the U.S. Department of Energy, Office of Health and Environmental Research, under Contract No. W-31-109-ENG-38 and by U. S. Public Health Service Grant DK43757.

**PS04.15.17 CRYSTAL STRUCTURE OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR COMPLEXES WITH AN INHIBITORY FAB.** Mingdong Huang, Rashid J. Syed, Enrico A. Stura, Wolfram Ruf, Thomas S. Edgington, and Ian A. Wilson. Department of Molecular Biology The Scripps Research Institute, La Jolla, CA 92037.

The macromolecular assembly of Tissue factor (TF) with factor VIIa plays the central role in the cellular activation of the blood coagulation cascades. An Fab (5G9) was found to be an effective immediate anticoagulant in plasma, which binds strongly to TF and displaces VIIa from the preformed TF-VIIa complex. We report here the crystal structure of the complex between Fab 5G9 and the extracellular domain of TF. The interdomain angle of TF in the complex is basically the same as for the free TF, demonstrating the strong interdomain interaction in TF. The current model of the complex is consistent with the TF mutagenesis data. For example, K169 and N171 interact with L1, L2, L3, and H3 CDR loops of Fab 5G9 with large contact area (138Å<sup>2</sup>), which explains when these residues are mutated to alanines both the binding of TF to Fab 5G9 and TF's function are greatly reduced. The TF-Fab complex is the first protein structure in P2 space group (based on current pdb release). The L shape of the complex molecule may explain the adoption of this rare space group for protein and the weak diffraction of the crystal. The crystal used for data collection diffracted to 3Å with an overall  $I/\sigma(I)$  of 7.5 and an R<sub>symm</sub> of 13%. The structure is currently refined to an R value of 24.0% and an R-free of 28.5% with strict NCS applied to the two NCS-related molecules in the asymmetric unit.

**PS04.15.18 PRELIMINARY STRUCTURAL FEATURES OF HUMAN HEPARIN BINDING PROTEIN.** Lars F. Iversen, Jette S. Kastrop and Ingrid Kjølner Larsen. Dept. of Medicinal Chemistry, Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen.

The highly glycosylated protein, human heparin binding protein (HBP) also known as CAP37 or Azurocidin has been crystallised in the primitive orthorhombic space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>. A full data set has been collected to 2.8 Å and diffraction was observed to at least 2.2 Å. A molecular replacement solution using human neutrophil elastase as a search model was obtained, showing one monomer per asymmetric unit. The correlation coefficient and R-factor were 50.4 and 44.8%, respectively, after 10 cycles of rigid body refinement.

HBP is an inactive serine protease homologue [1]. The inactivity is caused by selective mutations in the serine 195 and histidine 57 in the active site triade. The human HBP exhibits 47% sequence identity with human neutrophil elastase [1]. HBP consist of 225 amino acids, is highly glycosylated and possess three putative N-glycosylation sites. Human HBP has been expressed in the baculo virus system as a 28 kDa protein, resulting in a glycosylation degree of 13-14%.

HBP is believed to be involved in host defence during infections and inflammations [2]. Monocyte chemotaxis, survival and differentiation are activated by HBP [1,3]. In addition, it has been shown that HBP binds strongly to endotoxin with  $K_{ass} = 0.8 \times 10^9$